GBMA
Halve the PBS co-payment for biosimilars: GBMA
Reducing out-of-pocket costs and strengthening biosimilar uptake will deliver savings for people struggling with cost of living, says leading association The Generic and Biosimilar Medicines Association (GBMA) has proposed three …
Stockholding relief for select brands
Medication sponsors secure relief from minimum stockholding requirements for close to 270 Pharmaceutical Benefits Scheme (PBS) listed brands Requirements for drug sponsors to hold four to six-month supplies of …
PBS biosimilar drive more important than ever
Two new representatives have been welcomed to the GBMA Board, including a former pharmacist The Generic and Biosimilar Medicines Association Independent Chair, Professor Jane Halton and CEO, Marnie Peterson, welcomed …
Generics ‘security’ stockpile details revealed
List of “designated brands” shows what wholesalers must keep on stock to avoid shortages as part of industry deal The list of almost 3000 drugs pharmaceutical wholesalers will be compelled …
The pandemic strikes back
We titled our review of 2020 “A year like no other”. How wrong could we have been? Let’s look back at the second half of 2021… July • Sydney and …
Bigger onshore generic medicines stockpiles on the way
Health Minister announces new Medicines Supply Security Guarantee to prevent shortages as part of deals with pharma industry Generic medicines companies will start to hold a minimum of four to …
Keeping up with biosimilars
Pharmacy has a prominent role in the supply and provision of biosimilar medicines, and the profession has been slow to come to terms with this. Is the situation now changing? …
Returning to the fray
Leading health bureaucrat returns to head up generics and biosimilars peak body Jane Halton, former Secretary of the Department of Health has been appointed as the inaugural independent chair of …
Stakeholders reject Interim Report options
Members of the Medicines Partnership of Australia have banded together to raise concerns about the future stability of pharmacy The stakeholders, which include the Guild, PSA, ASMI, Generic and Biosimilar …
Therapeutic goods streamlining welcomed
Australia can streamline the regulation of therapeutic goods by removing duplicative and inefficient processes without undermining the safety and quality of medicines, the GBMA says following the Government’s response to …
Absence of more PBS reform honours commitment
The 2016 Budget confirms the significant ongoing PBS savings provided by generic medicines, and signals the government’s intent to streamline medicine regulation processes, says GBMA. The absence of further PBS …
Evergreening delays access: GBMA
Evergreening strategies delay market entry for generic medicines to the detriment of the Australian community and there is a lack of evidence to support extending market exclusivity for pharmaceuticals, according …